A real contribution of AI is showing the critical weaknesses of humans and human structures.

open-sourcing CTDs is extremely exciting. we have found clinical protocols available on clinicaltrials.gov to be extremely helpful at y-trap. this will be an OOM jump beyond that in utility, especially for lean teams without decades of regulatory experience.

CTD Commons will preserve and publish regulatory knowledge from failed drug development programs so future teams can learn from precedent that is usually locked away, to help uncover effective treatments for patients faster. A CTD, or Common Technical Document, is a document that compiles the full journey of an investigational drug – everything from animal toxicology, manufacturing details, and, perhaps most usefully, correspondence with the FDA. Yet only a small fraction of that work appears in published papers. CTD Commons will test the possibility of acquiring CTDs from failed or shelved drug programs, and make them openly available for research and analysis, for everyone to use. @antonioregalado wrote about the project, and @RuxandraTeslo's essay on the topic, here: nitter.net/antonioregalado/status…

We already know what a world without work looks like. It's the life of 18th century aristocrats, who concerned themselves with political gossip and petty dramas; of society ladies in the 1980s, who spent their time hosting and volunteering; and Italian-Americans in 1950s Boston, whose status was centered around their peer groups, rather than their jobs. Relational living comes to us naturally, but – argues @clarabcollier – work offers us dignity, structure, and meaning, as evinced by surveys that consistently find that about 85% of Americans are "somewhat" or "completely" satisfied by their jobs. Work gives us an escape from the cliquishness of relational societies: without it, our personal relationships might become even more stifling and transactional.

Huge get. Dan is great and has led some of the most innovative work at the Gates Foundation in recent years. Excited to continue working with him in this new role!

Neat paper: Women lose weight: - Life drastically changes - Men start approaching, a third partner off ASAP Men lose weight: - Their weight decreases

This is one of the reasons we were excited to invest in @CurevoVaccine (recently announced acquisition by Eli Lilly). An improved shingles vaccine could have a huge impact on public health. Every day, we learn more about the impacts of viral infections on our long-term health. I predict preventing them will become more and more of a priority for the industry in the coming years.

What’s driving these changes? You can outsource early stage science to China for 1/5 of the cost at 2x the speed.

The largest and sharpest image ever taken of the Andromeda galaxy — otherwise known as M31. It is the biggest Hubble image ever released and shows over 100 million stars, thousands of star clusters in a section of the galaxy’s disc stretching across over 40 000 light-years.

This is a hilariously disappointing result: 15% of placebo GLP-1 patients seemingly realized they weren't getting the real stuff and so they went out and got it on their own. They're undermining the trials because they want to lose weight!

'The surge in new US business formation is being fueled by AI and large language models, which are dramatically reducing the cost and complexity of launching a company' @apolloglobal

Something that is underappreciated is China has 4x the population and Tier 1 cities are 30 million people, so easier to recruit and finish studies. However, their Phase 1 process is more like Australia and have more silent approval; if you don’t hear from us, proceed. Australia is fast for Phase 1 and they have more silent approval, but they are just doing safety and know the pivotal trials will primarily be done in US & other countries. FDA tends to view Phase 1 as precedent for the entire drug program all the way through Phase 3, so they want everything to be in order from the start like CMC. I would say Australia doesn’t really care about CMC b/c that will be covered by US during trials and scale up. For Phase 1 just need smaller batch manufacturing, do not necessarily need to be set up with standards for Phase 2 or 3 larger trials, but it makes thing smoother.

bleak that the primary people who are worried about chinese biotech are people who actually work in the field, and everyone telling them to chill out are either VC’s or journalists